Long-Term Tolerability and Safety of HYQVIA/HyQvia in CIDP

PHASE3CompletedINTERVENTIONAL
Enrollment

85

Participants

Timeline

Start Date

November 14, 2016

Primary Completion Date

July 4, 2023

Study Completion Date

July 4, 2023

Conditions
Chronic Inflammatory Demyelinating Polyradiculoneuropathy
Interventions
BIOLOGICAL

HYQVIA

Participants received HYQVIA/HyQvia SC which contains both Immune Globulin Infusion 10% (Human) (IGI, 10%) and recombinant human hyaluronidase (rHuPH20).

Trial Locations (35)

1280

Hosp.Britanico de Buenos Aires, Ciudad Autonoma Buenos Aires

8000

Århus Universitetshospital, Aarhus C

11000

Clinical Center of Serbia, Belgrade

Military Medical Academy, Belgrade

14080

Instituto Nacional de Ciencias Médicas y Nutricion Dr. Salvador Zubiran, Mexico City

16132

Azienda Ospedaliero Universitaria San Martino, Genova

18000

Clinical Center Nis, Niš

20070

Pamukkale Uni. Med. Fac., Denizli

26504

University Hospital of Patra, Pátrai

27100

Fondazione Istituto Neurologico Casimiro Mondino, Pavia

33076

Groupe Hospitalier Pellegrin - Hôpital Pellegrin, Bordeaux

33100

Azienda Ospedaliero-Universitaria Santa Maria della Misericordia, Udine

35340

Dokuz Eylul University Faculty of Medicine, Izmir

42075

Selcuk Universitesi Selcuklu Tip Fakultesi Hastanesi, Konya

45030

Celal Bayar University Medical Faculty, Manisa

56126

Azienda Ospedaliero Universitaria Pisana, Pisa

69677

Hopital Neurologique Pierre Wertheimer, Bron

85028

Arizona Neuromuscular Research Center, Phoenix

95001

Fakultna nemocnica Nitra, Nitra

98122

Azienda Ospedaliera Universitaria Policlinico G. Martino, Messina

81210-310

Instituto de Neurologia de Curitiba - Hospital Ecoville, Curitiba

T6G 2B7

University of Alberta Hospital, Edmonton

N6A 5A5

LHSC - University Hospital, London

M5G 2C4

Toronto General Hospital, University Health Network, Toronto

050010

"Institucion Prestadora de Servicios de Salud de la Universidad de Antioquia IPS UNIVERSITARIA", Medellín

708 52

Fakultni nemocnice Ostrava, Ostrava

150 06

Fakultni nemocnice v Motole, Prague

06002

CHU de Nice, Nice

04103

Universitaetsklinikum Leipzig AoeR, Leipzig

80-952

Uniwersyteckie Centrum Kliniczne, Gdansk

90-153

Uniwersytecki Szpital Kliniczny nr 1 im. Norberta Barlickiego, Lodz

20-090

Samodzielny Publiczny Szpital Kliniczny Nr 4 w Lublinie, Lublin

08035

Hospital Universitari Vall d'Hebron, Barcelona

SE5 9RS

King's College Hospital, London

L9 7LJ

The Walton Centre, Liverpool

All Listed Sponsors
collaborator

Takeda Development Center Americas, Inc.

INDUSTRY

lead

Baxalta now part of Shire

INDUSTRY

NCT02955355 - Long-Term Tolerability and Safety of HYQVIA/HyQvia in CIDP | Biotech Hunter | Biotech Hunter